D.E. Shaw & Co
AVIR icon

D.E. Shaw & Co’s Atea Pharmaceuticals AVIR Stock Holding History

D.E. Shaw & Co’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Sell
345,186
-34,128
-9% -$170K ﹤0.01% 3385
2026
Q1 		$2.04M Sell
379,314
-85,473
-18% -$393K ﹤0.01% 2893
2025
Q4 		$1.66M Buy
464,787
+100,019
+27% +$318K ﹤0.01% 3199
2025
Q3 		$1.06M Buy
364,768
+168,916
+86% +$577K ﹤0.01% 3420
2025
Q2 		$705K Sell
195,852
-148,693
-43% -$443K ﹤0.01% 3465
2025
Q1 		$1.03M Buy
344,545
+88,462
+35% +$276K ﹤0.01% 3069
2024
Q4 		$858K Buy
256,083
+62,505
+32% +$208K ﹤0.01% 3290
2024
Q3 		$648K Buy
193,578
+45,665
+31% +$166K ﹤0.01% 3557
2024
Q2 		$490K Sell
147,913
-59,846
-29% -$223K ﹤0.01% 3636
2024
Q1 		$839K Buy
207,759
+22,582
+12% +$88.4K ﹤0.01% 3208
2023
Q4 		$565K Buy
185,177
+115,228
+165% +$349K ﹤0.01% 3455
2023
Q3 		$210K Sell
69,949
-13,473
-16% -$45.8K ﹤0.01% 3744
2023
Q2 		$312K Buy
83,422
+33,724
+68% +$126K ﹤0.01% 3585
2023
Q1 		$166K Buy
49,698
+9,476
+24% +$38.4K ﹤0.01% 3937
2022
Q4 		$193K Buy
40,222
+11,065
+38% +$56K ﹤0.01% 4258
2022
Q3 		$166K Buy
+29,157
New +$223K ﹤0.01% 4513
2022
Q1 		– Sell
-19,404
Closed -$173K – 5516
2021
Q4 		$173K Buy
+19,404
New +$302K ﹤0.01% 4933
2021
Q2 		– Sell
-28,187
Closed -$1.74M – 4740
2021
Q1 		$1.74M Buy
+28,187
New +$1.9M ﹤0.01% 2708

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co's AVIR Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Atea Pharmaceuticals (AVIR) stake by 9% in Q2 2026, selling an estimated $170K and leaving 345,186 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3385.

D.E. Shaw & Co first reported a position in AVIR in Q1 2021 and has held it in 18 quarters since. The position peaked at $2.04M in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • D.E. Shaw & Co held 345,186 shares of Atea Pharmaceuticals worth $1.61M as of Q2 2026.
  • D.E. Shaw & Co sold 34,128 Atea Pharmaceuticals shares in Q2 2026, an estimated $170K.
  • Atea Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3385 holding.
  • D.E. Shaw & Co first reported a position in Atea Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
  • D.E. Shaw & Co's Atea Pharmaceuticals position peaked at $2.04M in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.